Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL.

Drug Category : Array
Conference Category : Array
Lead Author : Burke J, et al.
Published Date : 20/06/2015
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/UTX%20IB%20Lugano%20Slide%20Deck%20FINAL.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top